Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Aspirin resistance and genetic polymorphisms.

Josie A Cambria-Kiely1, Pritesh J Gandhi

  • 1Massachusetts College of Pharmacy and Health Sciences-Worcester, Worcester, MA 01608, USA.

Journal of Thrombosis and Thrombolysis
|March 26, 2003
PubMed
Summary

Genetic variations can influence aspirin response. Certain polymorphisms may cause aspirin resistance, increasing cardiovascular risk and necessitating alternative treatments for affected individuals.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and Tolerability of Zenocutuzumab in Advanced <i>NRG1</i> Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.

The New England journal of medicine·2018
Same author

Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study.

Neurology·2015
Same author

Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia.

Leukemia & lymphoma·2011
Same author

Randomized Trial of a Pharmacist-Delivered Intervention for Improving Lipid-Lowering Medication Adherence among Patients with Coronary Heart Disease.

Cholesterol·2011
Same author

Lepirudin-induced thrombocytopenia following subcutaneous administration.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2009

Area of Science:

  • Pharmacogenomics
  • Cardiovascular Medicine
  • Molecular Biology

Background:

  • Individual responses to drugs like aspirin (ASA) vary due to genetic differences.
  • Aspirin is widely used for preventing ischemic events, but its effectiveness can be compromised by genetic factors.
  • Limited research exists on the link between genetic polymorphisms and aspirin's clinical effects.

Purpose of the Study:

  • To explore the relationship between specific genetic polymorphisms and aspirin resistance.
  • To identify genetic variations that may predict an increased risk of cardiovascular events despite aspirin therapy.
  • To inform personalized treatment strategies for patients with genetic predispositions to aspirin resistance.

Main Methods:

  • Review of published literature on genetic polymorphisms affecting drug response.
  • Identification of key prothrombotic genetic variations potentially influencing aspirin efficacy.
  • Analysis of polymorphisms in genes such as cyclooxygenase-1 (COX-1), COX-2, glycoprotein IIIa (GPIIIa), and GP Ia/IIa.

Main Results:

  • Several genetic variations are associated with aspirin resistance and increased cardiovascular risk.
  • These include polymorphisms in COX-1 (Ser529), COX-2 mRNA overexpression, GPIIIa (PLA1/A2), and GP Ia/IIa (807T/873A).
  • Individuals with these polymorphisms may not achieve adequate antithrombotic effects from aspirin.

Conclusions:

  • Genetic polymorphisms can lead to aspirin resistance and a higher risk of ischemic vascular events.
  • Patients identified as carriers of these specific genetic variations may require alternative or additional antithrombotic therapies.
  • Personalized medicine approaches incorporating genetic testing can optimize treatment selection and improve outcomes.

Related Experiment Videos